It's mostly good news.

Anecdotes and data often appear side by side in news stories about the pandemic. And data can be interpreted in multiple ways. Here’s what to look for. With COVID-19, a news story that may be 100% accurate can still unintentionally mislead readers about the greatest threats of the pandemic. The unintended outcome results from a lesson taught to every journalism student: Use “real people” to “humanize” the news. Read Full Story

A staggering 66% say they avoid COVID-19 news because “they are primarily worried about the effect it has on their mood.” For the first several months after the COVID-19 pandemic went widespread, it seemed like people couldn’t get enough news about it. Matter of fact, traffic to the world’s top news sites surged by 54% by late March. Now, however, it appears that people are starting to avoid news sites even as the pandemic continues to spread. Read Full Story

Yes, it’s very good news—yet it’s important to keep hopes and expectations in check. Nothing is certain yet. There’s some massive news out about COVID-19—and it’s good for a change. Pfizer and BioNTech’s vaccine is reportedly successful in preventing over 90% of infections according to early data from its phase 3 study , says STAT News. Needless to say, if the data holds as the study continues, this vaccine could be the thing that turns the tide of the COVID-19 pandemic in humanity’s favor. Read Full Story

Nearly no people under age 20 need hospitalization. The CDC just speed-published a study of the first 4,226 reported U.S. COVID-19 cases, and the news is not good: Read Full Story

The debate was moderated by NBC News' Kristen Welker and focused on six main topics: COVID-19, race, climate change, national security, leadership, and American families.

Increasing your brand’s share of voice in news media and taking advantage of positive attributes these environments provide not only makes your advertising more effective, it’s likely to weaken your competitor’s position too.

Moderna reported positive Phase I testing results for its COVID-19 vaccine and will begin Phase III testing it on 30,000 humans in two weeks. News! Moderna reported positive Phase I testing results for its COVID-19 vaccine and will begin Phase III testing it on 30,000 humans in two weeks. (Separate Phase II trials are underway.) “No matter how you slice this, this is good news,” Dr. Anthony Fauci, our national bearer of bad news, told the Associated Press. Read Full Story

Preliminary research indicates that a common vaccine, called the BCG vaccine, may offer significant protection against COVID-19. Good news: Preliminary research indicates that a common vaccine, called the BCG vaccine, may offer significant protection against COVID-19. Here’s what you need to know: Read Full Story

U.S. stock futures are down this morning in premarket trading. U.S. stock futures are down this morning in premarket trading, as the world reacts to news that President Donald Trump has tested positive for COVID-19. Read Full Story